Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer

BJU International

Volumn 109, Issue 4, 2012, Pages 508-513

  Loeb, Stacy ^a   Metter, E Jeffrey ^b   Kan, Donghui ^c   Roehl, Kimberly A ^d   Catalona, William J ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

prostate cancer; PSA; PSA velocity; risk count; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FAMILY HISTORY; GLEASON SCORE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PATIENT ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN VELOCITY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84857034566     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10900.x     Document Type: Article

References (27)

1. Kvale R, Auvinen A, Adami HO, et al,. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007; 99: 1881-7 (Pubitemid 351767195)
2. Sirovich BE, Schwartz LM, Woloshin S,. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003; 289: 1414-20 (Pubitemid 37430309)
3. Chan EC, Barry MJ, Vernon SW, Ahn C,. Brief report: physicians and their personal prostate cancer-screening practices with prostate-specific antigen. A national survey. J Gen Intern Med 2006; 21: 257-9
4. Ross LE, Berkowitz Z, Ekwueme DU,. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008; 17: 636-44 (Pubitemid 351469214)
5. Andriole GL, Crawford ED, Grubb RL III, et al,. Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 years of follow-up. J Natl Cancer Inst 2012; [Epub ahead of print]
6. Schroder FH, Hugosson J, Roobol MJ, et al,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
7. Hugosson J, Carlsson S, Aus G, et al,. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32
8. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ,. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 2011; 29: 464-7
9. Vickers AJ, Savage C, O'Brien MF, Lilja H,. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27: 398-403
10. D'Amico AV, Chen MH, Roehl KA, Catalona WJ,. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-35
11. D'Amico AV, Renshaw AA, Sussman B, Chen MH,. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 440-7 (Pubitemid 41124176)
12. Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ,. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 2007; 70: 685-90 (Pubitemid 350030209)
13. Smith DS, Catalona WJ,. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994; 152: 1163-7 (Pubitemid 24283458)
14. Loeb S, Roehl KA, Nadler RB, Yu X, Catalona WJ,. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/mL. J Urol 2007; 178: 2348-53 (Pubitemid 350052163)
15. Loeb S, Roehl KA, Helfand BT, Kan D, Catalona WJ,. Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol 2010; 183: 112-6
16. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Accessed December 2011
17. Thompson IM, Pauler DK, Goodman PJ, et al,. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
18. Cook NR,. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-35 (Pubitemid 46294733)
19. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS,. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-72 (Pubitemid 351193639)
20. Walsh PC, Lepor H, Eggleston JC,. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 1983; 4: 473-85 (Pubitemid 14236144)
21. Sanda MG, Dunn RL, Michalski J, et al,. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250-61 (Pubitemid 351439226)
22. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT,. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006; 98: 1134-41 (Pubitemid 44288788)
23. Klotz L,. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005; 23: 8165-9 (Pubitemid 46211550)
24. Carter HB, Ferrucci L, Kettermann A, et al,. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98: 1521-7 (Pubitemid 44680903)
25. Wolters T, Roobol MJ, Bangma CH, Schroder FH,. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol 2009; 55: 385-92
26. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM,. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349: 335-42 (Pubitemid 36886239)
27. Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JA, Catalona WJ,. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol 2006; 24: 465-71 (Pubitemid 44810008)